The global acute migraine drugs market is expected to reach USD 9.26 billion by 2030, at a CAGR of 8.90% from 2022 to 2030. Acute migraine drug market growth would be driven by the increasing need for migraine therapy, growing demand from pharmaceutical enterprises, hospitals, and medical research laboratories, and the rising number of manufacturers.
The global acute migraine drugs market is anticipated to grow due to the increasing majority of neurological disorders, growing workload, increased alcohol consumption, lifestyle changes, and increasing demand for quality drugs. Similarly, the increased patient awareness about migraine control therapy and the understanding of migraine and its treatment leads to market development. Rising research & development investment, resulting in an extensive pipeline of medicines, are essential drivers anticipated to boost the market's development. Regardless, a lack of proper undiagnosed and diagnosed cases, drug side effects, strict government regulations, and a growing tendency for alternative treatments are significant limitations to the market's development. Signs like numbness, nausea, vomiting, and trouble speaking may be present. An alert sensation called an aura develops before or with some individuals' headaches. Optical disturbances, like a flashlight or blind patches, or other troubles, such as tingling on one side of the face, arm, or leg, and difficulty communicating, may all be an atmosphere. Migraine is a neurological disorder that induces headaches, sickness, incapacity to smell, expanded sensitivity to sound and light, and numbness, among additional symptoms.
Get an overview of this study by requesting a free sample
The increased need for high-quality drugs and rising awareness among individuals about the prevention & treatment of migraine is expected to support the sales of acute migraine treatment options. The growing consumption of alcoholic drinks, rising smoking patterns, and the advancement in work pressure are other factors expected to predict well for the global market.
Headache, sleepiness, nausea, dry mouth, dizziness, fatigue, hot or cold sensations, chest pain, flushing, sense of tightness around the chest or throat, numbness. These medications cause the narrowing of the blood vessels. People shouldn't take these medications if they have a history of coronary artery disease, myocardial infarction, or stroke. It's not good for them.
The growth in the majority of migraine cases globally is one of the essential factors propelling the expansion of the migraine drugs market. The technological advancement in R&D in pharmaceutical enterprises for improving different types of migraine drugs accelerate market growth. The rising awareness among patients about the prevention and therapy of migraine and the increase in the partnerships among manufacturers further impact the market development.
The global acute migraine drugs market has been segmented based on route of administration, treatment, end user, and regions.
The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America region emerged as the largest market for the global acute migraine drugs market, with a 34.5% share of the market revenue in 2021.
North America is anticipated to lead the acute migraine drugs market stake in the evaluation time. The increasing investment by essential players established in the United States and Canada in comprehensive research and development actions to find other treatment choices is assessed to predict satisfactorily for the regional market.
North America Region Acute Migraine Drugs Market Share in 2021 - 34.5%
www.thebrainyinsights.com
Check the geographical analysis of this market by requesting a free sample
The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances, and partnerships to improve their market position in the global acute migraine drugs industry.
In February 2022, Pfizer Inc. and Bio haven Pharmaceutical Company Ltd. declared that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) authorized Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist.
As per The Brainy Insights, the size of the acute migraine drugs market was valued at USD 4.3 billion in 2021 to USD 9.26 billion by 2030.
Global acute migraine drugs market is growing at a CAGR of 8.90% during the forecast period 2022-2030.
The global acute migraine drugs market has been segmented based on route of administration, treatment, end user, and regions. The oral segment led the market in 2021. The preventive segment led the market in 2021.
North America region emerged as the largest market for the acute migraine drugs market.
The increased demand for high-quality medicines to propel market growth.
Side-effects of drugs specified for migraine to hinder market growth.
Technological advancements will provide huge opportunities to the market.
Key players are Teva Pharmaceutical, Pfizer Inc., Novartis AG, Merck & Co., Johnson and Johnson, Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca, and Amgen.
1. Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Research Scope
1.4. Currency
1.5. Key Target Audience
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market Attractiveness Analysis by Route of Administration
4.3.2. Market Attractiveness Analysis by Treatment
4.3.3. Market Attractiveness Analysis by End-User
4.3.4. Market Attractiveness Analysis by Region
4.4. Industry Trends
5. Market Dynamics
5.1. Market Evaluation
5.2. Drivers
5.2.1. The increased demand for high-quality medicines
5.3. Restraints
5.3.1. Side-effects of drugs specified for migraine
5.4. Opportunities
5.4.1. Technological advancements
6. Global Acute Migraine Drugs Market Analysis and Forecast, By Route of Administration:
6.1. Segment Overview
6.2. Injection
6.3. Oral
6.4. Others
7. Global Acute Migraine Drugs Market Analysis and Forecast, By Treatment
7.1. Segment Overview
7.2. Pain Relieving
7.3. Preventive
8. Global Acute Migraine Drugs Market Analysis and Forecast, By End-User
8.1. Segment Overview
8.2. Online Pharmacies
8.3. Retail Pharmacies
8.4. Hospital Pharmacies
9. Global Acute Migraine Drugs Market Analysis and Forecast, By Regional Analysis
9.1. Segment Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.5. South America
9.5.1. Brazil
9.6. Middle East and Africa
9.6.1. UAE
9.6.2. South Africa
10. Global Acute Migraine Drugs Market-Competitive Landscape
10.1. Overview
10.2. Market Share of Key Players in the Acute Migraine Drugs Market
10.2.1. Global Company Market Share
10.2.2. North America Company Market Share
10.2.3. Europe Company Market Share
10.2.4. APAC Company Market Share
10.3. Competitive Situations and Trends
10.3.1. Product Launches and Developments
10.3.2. Partnerships, Collaborations, and Agreements
10.3.3. Mergers & Acquisitions
10.3.4. Expansions
11. Company Profiles
11.1. Teva Pharmaceutical
11.1.1. Business Overview
11.1.2. Company Snapshot
11.1.3. Company Market Share Analysis
11.1.4. Company Product Portfolio
11.1.5. Recent Developments
11.1.6. SWOT Analysis
11.2. Pfizer Inc
11.2.1. Business Overview
11.2.2. Company Snapshot
11.2.3. Company Market Share Analysis
11.2.4. Company Product Portfolio
11.2.5. Recent Developments
11.2.6. SWOT Analysis
11.3. Novartis AG
11.3.1. Business Overview
11.3.2. Company Snapshot
11.3.3. Company Market Share Analysis
11.3.4. Company Product Portfolio
11.3.5. Recent Developments
11.3.6. SWOT Analysis
11.4. Merck & Co.
11.4.1. Business Overview
11.4.2. Company Snapshot
11.4.3. Company Market Share Analysis
11.4.4. Company Product Portfolio
11.4.5. Recent Developments
11.4.6. SWOT Analysis
11.5. Johnson and Johnson
11.5.1. Business Overview
11.5.2. Company Snapshot
11.5.3. Company Market Share Analysis
11.5.4. Company Product Portfolio
11.5.5. Recent Developments
11.5.6. SWOT Analysis
11.6. Hoffmann-La Roche Ltd
11.6.1. Business Overview
11.6.2. Company Snapshot
11.6.3. Company Market Share Analysis
11.6.4. Company Product Portfolio
11.6.5. Recent Developments
11.6.6. SWOT Analysis
11.7. Eli Lilly and Company
11.7.1. Business Overview
11.7.2. Company Snapshot
11.7.3. Company Market Share Analysis
11.7.4. Company Product Portfolio
11.7.5. Recent Developments
11.7.6. SWOT Analysis
11.8. AstraZeneca.
11.8.1. Business Overview
11.8.2. Company Snapshot
11.8.3. Company Market Share Analysis
11.8.4. Company Product Portfolio
11.8.5. Recent Developments
11.8.6. SWOT Analysis
11.9. Amgen
11.9.1. Business Overview
11.9.2. Company Snapshot
11.9.3. Company Market Share Analysis
11.9.4. Company Product Portfolio
11.9.5. Recent Developments
11.9.6. SWOT Analysis
List of Table
1. Global Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
2. Global Injection Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion)
3. Global Oral Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion)
4. Global Others Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion)
5. Global Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
6. Global Pain-Relieving Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion)
7. Global Preventive Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion)
8. Global Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
9. Global Online Pharmacies Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion)
10. Global Retail Pharmacies Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion)
11. Global Hospital Pharmacies Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion)
12. North America Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
13. North America Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
14. North America Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
15. U.S. Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
16. U.S. Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
17. U.S. Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
18. Canada Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
19. Canada Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
20. Canada Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
21. Mexico Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
22. Mexico Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
23. Mexico Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
24. Europe Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
25. Europe Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
26. Europe Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
27. Germany Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
28. Germany Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
29. Germany Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
30. France Acute Migraine Drugs Market, By Route of Administration 2019-2030 (USD Billion)
31. France Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
32. France Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
33. U.K. Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
34. U.K. Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
35. U.K. Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
36. Italy Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
37. Italy Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
38. Italy Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
39. Spain Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
40. Spain Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
41. Spain Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
42. Asia Pacific Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
43. Asia Pacific Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
44. Asia Pacific Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
45. Japan Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
46. Japan Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
47. Japan Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
48. China Acute Migraine Drugs Market, By Route of Administration 2019-2030 (USD Billion)
49. China Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
50. China Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
51. India Acute Migraine Drugs Market, By Route of Administration 2019-2030 (USD Billion)
52. India Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
53. India Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
54. South America Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
55. South America Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
56. South America Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
57. Brazil Acute Migraine Drugs Market, By Route of Administration 2019-2030 (USD Billion)
58. Brazil Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
59. Brazil Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
60. Middle East and Africa Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
61. Middle East and Africa Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
62. Middle East and Africa Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
63. UAE Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion)
64. UAE Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
65. UAE Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
66. South Africa Acute Migraine Drugs Market, By Route of Administration 2019-2030 (USD Billion)
67. South Africa Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion)
68. South Africa Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)
List of Figures
1. Global Acute Migraine Drugs Market Segmentation
2. Acute Migraine Drugs Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Acute Migraine Drugs Market Attractiveness Analysis by Route of Administration
9. Global Acute Migraine Drugs Market Attractiveness Analysis by Treatment
10. Global Acute Migraine Drugs Market Attractiveness Analysis by End-User
11. Global Acute Migraine Drugs Market Attractiveness Analysis by Region
12. Global Acute Migraine Drugs Market: Dynamics
13. Global Acute Migraine Drugs Market Share by Route of Administration (2022 & 2030)
14. Global Acute Migraine Drugs Market Share by Treatment (2022 & 2030)
15. Global Acute Migraine Drugs Market Share by End-User (2022 & 2030)
16. Global Acute Migraine Drugs Market Share by Regions (2022 & 2030)
17. Global Acute Migraine Drugs Market Share by Company (2021)
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. The Brainy Insights has segmented the global acute migraine drugs Market based on below mentioned segments:
Global Acute Migraine Drugs Market by Route of Administration:
Global Acute Migraine Drugs Market by Treatment:
Global Acute Migraine Drugs Market by End User:
Global Acute Migraine Drugs Market by Region:
Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision.
Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.
The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.
Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:
The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.
The data procurement stage involves in data gathering and collecting through various data sources.
This stage involves in extensive research. These data sources includes:
Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:
Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.
Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.
The supply side for a domain specific market is analysed by:
The demand side for the market is estimated through:
In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.
Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:
Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:
Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.
This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.
Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.
The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:
Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.
Free Customization
Fortune 500 Clients
Free Yearly Update On Purchase Of Multi/Corporate License
Companies Served Till Date